56例新生儿肺动脉高压运用西地那非治疗的疗效和安全性初探(1)
[摘要] 目的 研究分析西地那非治疗新生儿肺动脉高压的临床效果及其安全性。 方法 整群选取2013年2月—2015年2月该院收治的新生儿肺动脉高压患儿112例，随机分为两组，各56例。对照组采用常规治疗，观察组采用西地那非治疗，对比两组治疗前后动脉血气和肺动脉压变化。 结果 观察组治疗后OI、PAP指标分别为(8.0±4.1)、(25.2±7.4)mmHg，显著低于对照组，差异有统计学意义(P<0.01)；观察组治疗后PaO2指标为(74.7±9.1)mmHg，显著高于对照组，差异有统计学意义(P<0.01)。 结论 西地那非治疗新生儿肺动脉高压效果显著，能够有效降低动脉氧合指数和肺动脉压，提高氧分压，值得推广。
[关键词] 西地那非；新生儿；持续肺动脉高压
[中图分类号] R56 [文献标识码] A [文章编号] 1674-0742(2016)02(c)-0100-02
Study on Curative Effect and Security of Sildenafil in Treatment of 56 Cases with Neonatal Pulmonary Hypertension
TAN Xin
Neonatal department， Zhengzhou maternal and child care service centre， Zhengzhou， Henan Province， 450052 China
[Abstract] Objective To research and analyze the clinical effect and its security of sildenafil in treatment of neonatal pulmonary hypertension. Methods 112 cases of children with neonatal pulmonary hypertension admitted and treated in our hospital from February 2013 to February 2015 were selected and randomly divided into two groups with 56 cases in each， the control group were treated with conventional method， the observation group were treated with sildenafil， the changes of arterial blood gas and pulmonary artery pressure of the two groups were compared. Results The indexes such as OI and PAP after treatment were respectively (8.0±4.1)mmHg and(25.2±7.4)mmHg， which were obviously lower than those in the control group， and the differences were statistically significant (P<0.01)， the PaO2 after treatment was (74.7±9.1)mmHg in the observation group， which was obviously higher than that in the control group， and the difference was statistically significant (P<0.01). Conclusion The effect of sildenafil in treatment of neonatal pulmonary hypertension is obvious， and it can effectively reduce the arterial oxygenation index and pulmonary artery pressure and is worth promotion.
[Key words] Sildenafil； Neonatal； Persistent pulmonary hypertension
新生儿肺动脉高压是一种常见危重疾病，其病死率较高[1]。临床认为对于新生儿肺动脉高压可以采用药物治疗方法，西地那非作为选择性血管扩张药，其能够有效降低肺动脉压，并且使用便捷，价格较低[2]。该研究中整群选择2013年2月—2015年2月该院收治的新生儿肺动脉高压患儿112例分别给予常规治疗和西地那非治疗，旨在探讨西地那非治疗新生儿肺动脉高压的疗效，现报道如下。
1 资料与方法
1.1 一般资料
整群选取2013年2月—2015年2月该院收治的新生儿肺动脉高压患儿112例，随机分为两组，各56例。对照组男38例，女18例；年龄2个月～4岁，平均年龄为(2.3±1.1)岁；平均胎龄为(37.5±1.5)周；平均体质量为(2.99±0.65)kg；平均PAP指标为(49.6±8.1)mmHg；平均BP指标为(64.5±17.3)mmHg，原发病为：胎粪吸入综合征(MAS) 15例、窒息14例、肺透明膜病(RDS) 6例、肺炎21例。观察组男35例，女21例；年龄3个月～5岁，平均年龄为(2.5±1.2)岁；平均胎龄为(37.4±2.3)周；平均体质量为(2.86±0.84)kg；平均PAP指标为(49.4±10.5)mmHg；平均BP指标为(62.5±18.2)mmHg，原发病为：胎粪吸入综合征(MAS) 16例、窒息15例、肺透明膜病(RDS)6例、肺炎19例。所有患儿机械通气过程中均伴随反复低氧血症和代谢性酸中毒等症状，且通过超声心动图确诊为新生儿持续肺动脉高压。两组一般资料对比，差异无统计学意义(P>0.05)。 (谭鑫)
[关键词] 西地那非；新生儿；持续肺动脉高压
[中图分类号] R56 [文献标识码] A [文章编号] 1674-0742(2016)02(c)-0100-02
Study on Curative Effect and Security of Sildenafil in Treatment of 56 Cases with Neonatal Pulmonary Hypertension
TAN Xin
Neonatal department， Zhengzhou maternal and child care service centre， Zhengzhou， Henan Province， 450052 China
[Abstract] Objective To research and analyze the clinical effect and its security of sildenafil in treatment of neonatal pulmonary hypertension. Methods 112 cases of children with neonatal pulmonary hypertension admitted and treated in our hospital from February 2013 to February 2015 were selected and randomly divided into two groups with 56 cases in each， the control group were treated with conventional method， the observation group were treated with sildenafil， the changes of arterial blood gas and pulmonary artery pressure of the two groups were compared. Results The indexes such as OI and PAP after treatment were respectively (8.0±4.1)mmHg and(25.2±7.4)mmHg， which were obviously lower than those in the control group， and the differences were statistically significant (P<0.01)， the PaO2 after treatment was (74.7±9.1)mmHg in the observation group， which was obviously higher than that in the control group， and the difference was statistically significant (P<0.01). Conclusion The effect of sildenafil in treatment of neonatal pulmonary hypertension is obvious， and it can effectively reduce the arterial oxygenation index and pulmonary artery pressure and is worth promotion.
[Key words] Sildenafil； Neonatal； Persistent pulmonary hypertension
新生儿肺动脉高压是一种常见危重疾病，其病死率较高[1]。临床认为对于新生儿肺动脉高压可以采用药物治疗方法，西地那非作为选择性血管扩张药，其能够有效降低肺动脉压，并且使用便捷，价格较低[2]。该研究中整群选择2013年2月—2015年2月该院收治的新生儿肺动脉高压患儿112例分别给予常规治疗和西地那非治疗，旨在探讨西地那非治疗新生儿肺动脉高压的疗效，现报道如下。
1 资料与方法
1.1 一般资料
整群选取2013年2月—2015年2月该院收治的新生儿肺动脉高压患儿112例，随机分为两组，各56例。对照组男38例，女18例；年龄2个月～4岁，平均年龄为(2.3±1.1)岁；平均胎龄为(37.5±1.5)周；平均体质量为(2.99±0.65)kg；平均PAP指标为(49.6±8.1)mmHg；平均BP指标为(64.5±17.3)mmHg，原发病为：胎粪吸入综合征(MAS) 15例、窒息14例、肺透明膜病(RDS) 6例、肺炎21例。观察组男35例，女21例；年龄3个月～5岁，平均年龄为(2.5±1.2)岁；平均胎龄为(37.4±2.3)周；平均体质量为(2.86±0.84)kg；平均PAP指标为(49.4±10.5)mmHg；平均BP指标为(62.5±18.2)mmHg，原发病为：胎粪吸入综合征(MAS) 16例、窒息15例、肺透明膜病(RDS)6例、肺炎19例。所有患儿机械通气过程中均伴随反复低氧血症和代谢性酸中毒等症状，且通过超声心动图确诊为新生儿持续肺动脉高压。两组一般资料对比，差异无统计学意义(P>0.05)。 (谭鑫)